← All candidates
103 insider filings on record.
103 filings on record.
RNAAtrium Therapeutics, Inc.
—
$10.64
+2.70% · Sep 14
103 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · dailyNo open-market activity in range
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 1 move explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Short % float
Pro
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
98 more transactions on Pro →Context
Wall St
$25.00 avg target
+135.0% vs today · 3 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 1 quarters beat
Q1 '26−$0.97 act+$0.08
Coverage
Here's Why We're Not Too Worried About Atrium Therapeutics' (NASDAQ:RNA) Cash Burn SituationSimply Wall St. · 05-28Novartis Uses US Bond Issue To Expand RNA And Peptide PipelineSimply Wall St. · 03-19Novartis acquisition spin-off pioneers RNA therapeutics for the heartPharma Voice · 03-19Avidity (RNA) Moves Date for Shareholder Vote on Novartis MergerInsider Monkey · 02-27
The file stays open
103 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice